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ABSTRACT
Introduction: Homonymous hemianopia is a common
and disabling visual problem after stroke. Currently,
prism glasses and visual scanning training are
proposed to improve it. The aim of this trial is to
determine the effectiveness of these interventions
compared to standard care.
Methods and analysis: The trial will be a
multicentre three arm individually randomised
controlled trial with independent assessment at 6 week,
12 week and 26 week post-randomisation. Recruitment
will occur in hospital, outpatient and primary care
settings in UK hospital trusts. A total of 105 patients
with homonymous hemianopia and without ocular
motility impairment, visual inattention or pre-existent
visual field impairment will be randomised to one of
three balanced groups. Randomisation lists will be
stratified by site and hemianopia level (partial or
complete) and created using simple block
randomisation by an independent statistician.
Allocations will be disclosed to patients by the treating
clinician, maintaining blinding for outcome
assessment. The primary outcome will be change in
visual field assessment from baseline to 26 weeks.
Secondary measures will include the Rivermead
Mobility Index, Visual Function Questionnaire 25/10,
Nottingham Extended Activities of Daily Living, Euro
Qual-5D and Short Form-12 questionnaires. Analysis
will be by intention to treat.
Ethics and dissemination: This study has been
developed and supported by the UK Stroke Research
Network Clinical Studies Group working with service
users. Multicentre ethical approval was obtained
through the North West 6 Research ethics committee
(Reference 10/H1003/119). The trial is funded by the
UK Stroke Association. Trial Registration: Current
Controlled Trials ISRCTN05956042. Dissemination will
consider usual scholarly options of conference
presentation and journal publication in addition to
patient and public dissemination with lay summaries
and articles.
Trial Registration: Current Controlled Trials
ISRCTN05956042.
INTRODUCTION
Homonymous hemianopia results in loss of
one-half of the visual ﬁeld in both eyes.1 2
The reported prevalence of visual ﬁeld loss
following stroke has been as high as 63%3 in
hospital populations although estimates vary
widely as the proportion testing positive is
highly dependent on time post-stroke.
Homonymous hemianopia on admission is
linked to poor early survival and, conversely,
around 10%3 experience full spontaneous
recovery within the ﬁrst 2 weeks. Visual ﬁeld
defects can seriously impact on functional
ability and quality of life following stroke.4 5
Patients with visual ﬁeld defects have an
increased risk of falling,6 impaired ability to
read, poor mood and institutionalisation.6–9
Visual ﬁeld loss may impact on a patient’s
ability to participate in rehabilitation, and
may ultimately result in poor long-term
recovery.8 Visual ﬁeld loss can result in acci-
dents or injuries which have subsequent cost
implications to the National Health Service
and the patient.10
Service provision is presently inconsist-
ent.11 A recent survey of orthoptists has
shown that 45% of stroke services provided
no formal vision assessment for patients with
stroke.12 A further survey of current practice
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in stroke care in patient settings in Scotland identiﬁed
that only 7% of stroke units had a policy relating to
vision assessment and management.13 Both surveys illus-
trate the lack of standardisation of practice in relation to
visual impairment assessment and treatment for stroke
survivors. The Department of Health National Stroke
Strategy,14 argues that vision and visual perceptual difﬁ-
culties are components requiring multifaceted stroke
speciﬁc rehabilitation and support. The Royal College of
Physicians recently revised their guidance for stroke and
currently recommend that every patient who has had a
stroke should have a practical assessment of vision and
examination of the visual ﬁeld.15 They also advise that
any patient whose visual ﬁeld defect causes practical pro-
blems should be taught compensatory techniques with
prism treatment provided only by those with expertise in
this treatment. The Scottish Intercollegiate Guideline
Network (SIGN) guidelines for management of patient
with stroke (SIGN 118)16 17 advocates that all patients
with stroke should be screened for visual problems and
also suggests visual scanning compensatory training tech-
niques as potentially improving function outcomes after
stroke. The SIGN 118 guidelines also stress the need for
further high-quality research to investigate the effective-
ness of interventions for visual ﬁeld defects.
Two key interventions commonly used in the clinical
setting to improve vision in hemianopia are visual scan-
ning compensatory training and provision of prisms.13
We completed a literature search and identiﬁed a
number of reviews, which have investigated the efﬁcacy
of interventions for hemianopia after stroke.8 18–22 We
extracted data on any intervention studies investigating
visual scanning compensatory training or prisms and
searched for any subsequent or on-going randomised
controlled trials (RCTs).
A number of intervention studies have been con-
ducted for visual scanning compensatory training. There
is consistency between these studies in identifying bene-
ﬁts associated with scanning or eye movement training.
One RCT has reported on the use of either 15 dioptre
plastic press-on fresnel prisms or no prism treatment.
The results of this study demonstrated improvements in
visual impairment, but not in functional outcomes.23 It
was limited by the inclusion of patients with hemianopia
and neglect, by the small prism power and by use of
screening vision measures. We identiﬁed four longitu-
dinal studies of prism use. Bowers et al24 and Giorgi
et al25 completed prospective cohort studies, investigat-
ing Fresnel prism peripheral segments. The reported
outcome for these studies was ‘clinical success’, as mea-
sured by continued wear: 74% and 67% of participants,
respectively, were reported to continue to wear the
prisms at the end of the study, and 47% and 42%,
respectively, at long-term follow-up. In a study of 12
patients ﬁtted with 40 dioptre prisms, an effective expan-
sion of the visual ﬁeld (in the presence of prism wear
only) was reported of up to 20°26; however, there was no
control group included in this study.
Our aim is to undertake a pilot RCT to provide essen-
tial information for the conduct of a subsequent full
phase III study to determine the clinical and cost-
effectiveness of visual rehabilitation interventions as
compared to NHS standard care, in patients with hemi-
anopia following stroke. We wish to determine whether
visual rehabilitation is more effective than standard care
(advice only) at improving functional outcome in
patients with hemianopia following stroke, and whether
prism therapy or visual search therapy is more effective
at improving functional outcome in patients with hemi-
anopia following stroke.
METHODS AND ANALYSIS
This trial is a randomised controlled, multicentre trial.
Treatment with Fresnel prisms and treatment with visual
search strategies are compared to a control group of
standard care (advice only).The template for interven-
tion description and replication (TIDieR) checklist and
guide will be used when reporting the results of this trial.
Primary end point
Change of visual ﬁeld over time—from baseline to
26 weeks post baseline assessment. Visual ﬁeld will be
measured in degrees.
Secondary end points
Changes of outcomes A–F (see below) over time, from
baseline up to 26 weeks post baseline assessment.
A. Visual function questionnaire (VFQ 25–10): change
in perceived ability relating to activities of daily living
B. Rivermead Mobility Index: change in functional
mobility
C. Nottingham extended activities of daily living
(NEADL): change in instrumental activities
D. EQ-5D: change in health-related quality of life
E. SF-12: change of general health status
F. Radner test: change of reading speed and accuracy
Inclusion criteria
Patients with the following characteristics will be eligible
for inclusion in the trial:
A. 18 years of age or older;
B. Best corrected visual acuity of 0.5 or better in each
eye (left and right separately) at distance;
C. Stable homonymous hemianopia (partial or com-
plete) induced by stroke occurring more than
2 weeks ago but less than 26 weeks ago;
D. Refractive error within ±5 dioptres;
E. Willing and able to give consent for the study;
F. Prior to stroke able to read and understand English.
Vision measures will be established by orthoptic assess-
ment. Stroke will be deﬁned using WHO guidelines:
‘occurrence of rapidly developing signs of focal or
global disturbance of cerebral function, lasting longer
than 24 h or leading to death, with no apparent cause
other than that of vascular origin.’
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Exclusion criteria
All patients who do not meet the inclusion criteria listed
above will be excluded from the trial. Otherwise,
patients with the following characteristics will be
excluded from the trial:
A. Inability to consent due to severe cognitive
impairment;
B. Ocular motility impairment and/or visual inattention
in addition to the visual ﬁeld impairment (as
assessed by the orthoptist—saccadic impairment
introduced by the hemianopia is not an exclusion
criteria)
C. Pre-existent visual ﬁeld impairment due to previous
stroke.
We will not include patients who are recruited to
other trials or studies that treat visual problems.
Recruitment
Each week the Orthoptist will contact the admitting
ward (usually a stroke unit) to identify those patients
recently admitted with a stroke and suspected of having
homonymous hemianopia. The Orthoptist will liaise
with the stroke Research Nurse to identify these patients
and arrange appointments. All identiﬁed patients will be
contacted either in person if an in patient, or via tele-
phone for those who have been discharged. Patients will
be invited for eye assessment, conducted by the
Orthoptist in the eye clinic. Patients will be provided
with information sheets with full explanation of the trial
before obtaining informed written consent. Where the
patient is unable to write but is able to indicate consent,
witnessed consent will be obtained (ﬁgure 1).
All the patients who undergo screening will be
recorded on a ‘Screening Log’ regardless of whether
they decide to participate in the trial. Reasons patients
are not randomised, for example, not eligible will be
recorded. Reasons for declining to participate will be
asked routinely but it will be made clear that they do
not have to provide a reason unless happy to do so.
Enrolment/baseline
Once informed consent has been obtained from the
patient, the Orthoptist and Research Nurse will use the
baseline case report form to collect baseline character-
istics including patient demographics, visual signs and
symptoms, visual acuity measures, any additional ocular
problems or comorbidity, severity of stroke and level of
disability. The eligibility case report form will be com-
pleted by the Orthoptist. Patient completed question-
naires will also be collected.
Randomisation of a participant will take place once:
1. Eligibility assessment has been fulﬁlled;
2. Fully informed written consent has been obtained;
3. Baseline assessments, including visual ﬁeld assess-
ment and the degree of disability have been
completed.
Participants will be randomised using a secure (24 h)
web-based randomisation programme controlled
centrally by the Clinical Trials Research Centre.
Participant treatment allocation will be displayed on a
secure webpage and an automated email conﬁrmation
sent to the authorised randomiser, the Principal
Investigator (PI) and the trial coordinator. In case of
failure of this system, pre-prepared back up envelopes
will be available. It is the responsibility of the PI or dele-
gated research staff to ensure that sites have surplus ran-
domisation lists and back up envelopes throughout the
recruitment period to prevent any delays in the random-
isation process.
Method of randomisation
Participants will be individually randomised to the three
groups of equal size: treatment with prism therapy; treat-
ment with visual search training; or standard care
(advice only). Randomisation lists, stratiﬁed by centre
and degree of hemianopia (partial or complete), will be
produced by an independent statistician at the CTRC
using simple block randomisation. Outcome assessors
will remain blind to participant intervention. However,
due to the nature of the intervention, it is not possible
to blind other study personnel or the participant.
Interventions
Treatment with the allocated intervention will start
immediately following randomisation.
Arm A: treatment with prism therapy
All participants in this group will be given sector Fresnel
prisms of 40 prism dioptre strength on their glasses (or
plain glasses if not already worn) which displaces images
away from the affected side.26 Prisms are not placed over
central vision as this would cause double vision and
would therefore pose a risk for participant safety.
Consequently, by avoiding central vision, there are
limited side effects or risks to use of these prisms.
Separate prism segments are used to expand the upper
and lower quadrants. The prism shifts objects providing
a real ﬁeld of view expansion of degree comparable to
the prism power used, for example, 20° with 40 prism
dioptre. This results in ‘confusion’ or overlap of real and
shifted objects.
If the participant wears bifocals or varifocals the
prisms will be afﬁxed to alternative single lens/distance
glasses or plain glasses. If this is not possible only the
upper prism will be afﬁxed to the participants bifocalsor
varifocals. This will be captured on the case report
forms. Participants will require one Fresnel prism, which
is cut to ﬁt the upper and lower segment of one lens of
their glasses. The cutting and ﬁtting of the prism are
undertaken by a specialist Orthoptist who will ensure
that central gaze is not disrupted. Prior to ﬁtting the
prism will be inspected for any faults by the Orthoptist.
The participant will be instructed to maintain central
ﬁxation through their glasses. They will then be
instructed to use head movements to explore their ﬁeld
to the affected side when they become aware of an
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object of interest through the prism. The ﬁrst prism will
be placed at the participant’s ﬁrst visit; if possible the
second prism will also be ﬁtted at this time. However, if
the participant is not comfortable with both prisms
being ﬁtted at once, the second prism can be placed at
a second visit (2 weeks later, ±1 week) if no adaptation
difﬁculties to the ﬁrst prism have occurred. If adaption
difﬁculties have occurred the patient can continue with
only the ﬁrst prism and this will be captured on the case
report forms.
The prisms should be worn for a minimum of 2 h
daily from prism afﬁxation until 6-week follow-up visit as
a minimum, after this the patient can elect to continue
treatment if they wish. This information will be captured
on the case report forms and also the participant com-
pleted diaries will record whether the glasses were worn
for 2 h. This group will also receive the same informa-
tion leaﬂets as described for Arm C.
Arm B: treatment with visual search therapy
All participants in this group will be given visual search
training. This comprises an A4landscape card with hori-
zontal and diagonal numbered circles radiating out
from a central ﬁxation target. The participant will be
instructed to hold this at a distance of 8 inches from
their eyes (to ensure a wide ﬁeld of vision is utilised),
glasses can be worn as required. Participants will be
asked to transfer gaze quickly between printed targets
on the A4 card. The targets are printed off centre to the
right and left sides along the horizontal as well as
oblique planes to ensure stimulation of a wide area in
the blind and seeing parts of the visual ﬁeld.
Figure 1 Flow chart for trail.
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Participants will be instructed to continually scan
between the various targets for 30 min daily from base-
line until their 6-week follow-up, after which they can
elect to continue treatment if they wish. This informa-
tion will be captured on the case report forms and also
the participant completed diaries will record whether
the exercises were performed for 30 min continuously
or in blocks. Participants will be instructed on the scan-
ning exercises following randomisation to ensure their
understanding of the procedure of doing this training.
In addition, printed instructions will be provided with
the visual training target card. This group will also
receive the same information leaﬂets as described for
Arm C.
Arm C: control—standard care (advice only)
At time points according to local policy, the participant
will be given information leaﬂets from the Stroke
Association and the Royal National Institute for the
Blind (RNIB) about visual impairment following stroke.
All three arms will receive the same information
leaﬂets.
Assessment of compliance with trial treatments
Compliance with treatment up to the ﬁrst follow-up
appointment at 6 weeks is important and participants
and carers will be advised of the importance of contin-
ued treatment during this early time period.
Each participant will have a diary to record their com-
ments in relation to treatment and whether prisms,
visual search training or leaﬂets have been found beneﬁ-
cial or not. Usage of the prisms will be measured by
recording the continued wear of the prisms (taken from
the participant’s diary) and participants receiving the
visual search strategy treatment will be asked to keep a
diary of the time during each day when treatment was
undertaken and the duration.
The PI or research nurse will explain how to complete
the diaries before the participant leaves hospital.
Participants will be instructed to bring back the diary to
their follow-up visits.
Bias protection
Baseline assessments and randomisation will be con-
ducted prior to knowledge of allocation. Patient compli-
ance to group allocation will be followed up by
investigators to ensure that the treatment randomised is
given.
The chief investigator is masked to the randomisation
process and treatment groups. It is clearly not possible
to mask the local investigators (principal investigators
and research nurses) responsible for treating the
participants.
Treatment modifications
The participant will maintain their treatment allocation
until their 6-week follow-up visit. The participant can
then elect to continue treatment and this decision will
be captured on the follow-up visit case report forms and
also in the participant completed diaries. At the end of
the 26-week follow-up period the participant may con-
tinue their treatment as per local policy and for control
participants, may opt to undertake one of the trial treat-
ments if indicated and appropriate for them at that
time.
Schedule for follow-up
The expected follow-up of each participant is 26 weeks
with follow-up assessment at 6 week, 12 week and
26 week post-start of treatment. One-week windows
(±1 week) are allowable on the 6-week visit, while 2-week
windows (±2 weeks) are allowable for the 12-week and
26-week visits. Where possible, appointments will be
booked at the start of the follow-up visit window so that
if a participant does not or cannot attend their appoint-
ment, a further appointment can be remade within the
window. The participant will be contacted directly
regarding any failed appointment attendance. All visits
will be conducted in out-patient eye clinic departments
due to the location of visual ﬁeld perimeters in eye
clinics. Participants withdrawn from trial treatment will
be asked to continue with trial follow-up and attend the
follow-up visits. If a participant does not wish to con-
tinue in the trial, a Consent Withdrawal case report
form will be completed to capture the date and reason
for trial withdrawal. A minimum of the primary outcome
data will be collected for participants who withdraw from
trial treatment or for protocol deviations.
Procedures for assessing efficacy
Efﬁcacy of the trial treatments will be measured
throughout the period of the trial using objective and
subjective measures.
Baseline characteristics will include sex, date of birth,
date of stroke onset, type of stroke, location of stroke,
Barthel score and visual symptoms. Gold standard visual
ﬁeld assessment will consist of evaluation of the visual
ﬁeld in either eye as well as a binocular Esterman ﬁeld
of vision using Humphrey or Octopus automated perim-
etry and Goldmann manual perimetry with standard ﬁx-
ation monitoring strategies of ﬁxation loss, false-positive
and false-negative responses. Outcome measures will be
taken at the same time points of baseline, 6 week,
12 week and 26 week follow-up.
Visual field assessment
The visual ﬁeld assessment will be conducted by a quali-
ﬁed Orthoptist at baseline and at the 6-week, 12-week
and 26-week follow-up visits. An Esterman strategy is to
be used for quantitative visual ﬁeld assessment. This can
be performed using either:
▸ The Esterman programme on Humphrey or Octopus
perimetry;
▸ The III4e target on Goldmann with additional checks
of static points in the central visual ﬁeld.
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A template for Goldmann perimetry will be supplied
for standardisation which will match to the Esterman
strategy on Humphrey and Octopus perimetry. A binocu-
lar visual ﬁeld will be measured ﬁrst followed by mon-
ocular assessment of the right and left eyes. Where it is
not possible to use either of these methods then the
standardised confrontation method will be used.
Whichever method used at baseline must be duplicated
at the patient’s follow-up visits. Where the confrontation
method is used at baseline one of the above quantitative
methods must be used at the follow-up if possible in add-
ition to repeating the confrontation method.
Reading ability
Reading ability will be assessed by a qualiﬁed Orthoptist
at baseline and at the 6-week, 12-week and 26-week
follow-up visits using the Radner reading test.
Participant completed outcome measures
At baseline and the 6-week, 12-week and 26-week
follow-up visits the participant will be asked to complete
a questionnaire booklet containing the following
outcome measures:
▸ Visual function questionnaire (VFQ 25–10)
▸ Rivermead Mobility Index
▸ Nottingham extended activities of daily living assess-
ment (NEADL)
▸ ED-5Q
▸ Short Form-12 (SF-12)
All measures have been used extensively in previous
stroke research and are sensitive to change, valid and
reliable. Inclusion of each measure has been fully dis-
cussed and approved by the collaborative team and user
group involved in preparing the proposal for this trial.
Completion of the questionnaire booklets will ideally
precede any discussion with the PI or delegated other.
The PI or delegated other will ensure all questions have
been answered and that the randomisation number and
time point at which the booklet was administered are
recorded on the booklet. If the participant requires help
when completing the forms, because of difﬁculties with
writing, reading or aphasia, this will be recorded by the
PI.
Participants must complete the baseline booklet
before treatment allocation has been revealed. If the
participant is too unwell to receive the questionnaire
booklet or has missed at time point the research nurse
must inform the Clinical Trials Research Centre.
Sample size
There is little published on the recovery of visual ﬁeld
following stroke, and therefore, insufﬁcient data are
available to carry out a formal power calculation. The
proposed trial is designed to provide information for a
phase III trial to determine the effectiveness of visual
rehabilitation (prism glasses or visual search training)
compared to the standard care intervention in patients
with hemianopia following stroke.
We consider a sample of 30 participants per group will
obtain precise estimates of the parameters that are
required for the sample size calculation27 (variance of
visual ﬁeld per group, within-patient correlation—this is
the correlation between observations made at several
time points and loss to follow-up rates) as well as to gen-
erate sufﬁcient data on recruitment rates, compliance of
practitioners with randomisation and user views.
Additionally we increased the sample size needed per
group to 35 participants to allow for up to 15% drop out
from the study (based on stroke rehabilitation literature)
with the reasons for drop out being recorded (ie, a total
of 105 participants).
Analysis plan
The trial will be analysed and reported according to the
‘Consolidated Standard of Reporting Trials’
(CONSORT), TIDieR and the International Conference
on Harmonisation E9 guidelines. No formal statistical
interim analysis of the outcome data is planned. Interim
monitoring will focus on recruitment, safety and explora-
tory analysis to ensure baseline characteristics are
balanced between groups.
Data will be accessed by the trial team. A full and
detailed statistical analysis plan will be developed prior
to the ﬁnal analysis of the trial. The main features of the
statistical analysis plan are included here. Outcome ana-
lysis will be performed following an intention-to-treat
approach. The data collected will be used to estimate
the sample size required for a phase III trial based on
the analysis of covariance approach.28 Additionally, we
will apply a longitudinal linear mixed effects model to
explore changes in visual ﬁeld over time. A p value of
0.05 (5% level) will be used to declare statistical signiﬁ-
cant and 95% CIs of the estimated effects will be
reported. Rather than adjust for multiplicity relevant
results from other studies already reported in the litera-
ture will be taken into account in the interpretation of
results. Analysis will be undertaken to ensure that the
assumptions underlying the modelling techniques used
are met. As this trial is a pilot trial to establish sample
size parameters required for a full study and no adjust-
ment for multiplicity, all analyses will be treated as
exploratory and interpreted with caution.
ETHICAL CONSIDERATIONS
The study will abide by the principles of the World
Medical Association Declaration of Helsinki (1964) and
the Tokyo (1975), Venice (1983), Hong Kong (1989)
and South Africa (1996).
The trial protocol has been approved by the Health
Research Authority Multicentre Research Ethics
Committee (MREC) and by independent review at the
Research & Development (R&D) ofﬁces at participating
sites (Reference 10/H1003/119). All participants are
required to provide informed, written consent.
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Trial monitoring and oversight
Trial monitoring will be informed by the VISION risk
assessment and will be conducted as per the VISION
Trial Monitoring Plan to ensure that the rights and well-
being of human participants are protected during the
course of the clinical trial and that the data are credible
and accurate.
Data capture will be in the form of paper copies that
will be returned as an on-going process from each site to
the CTRC within 7 days of completion. All completed
forms for each patient will be expected within 7 days of
ﬁnal follow-up visit at 26 weeks.
The trial case report form (CRF) is the primary data
collection instrument for the trial. All data requested on
the CRF must be recorded and all missing data must be
identiﬁed and queried. CRFs will be photocopied at site
and the originals returned to the CTRC within 7 days of
the time speciﬁed for completion, unless stated other-
wise (photocopies of completed CRFs will be kept in the
site ﬁle).
Participants will complete the following questionnaires
at speciﬁed intervals (baseline and 6 week, 12 week and
26 week follow-up visits):
▸ VFQ 25-10
▸ EQ-5D
▸ SF-12
▸ NEADL
▸ Rivermead Mobility Index
▸ Treatment diary
The participant initials and randomisation number
will be clearly labelled on all these documents. Research
staff will also complete the relevant ‘centre use’ section
on the front cover of each questionnaire or diary.
Diaries and questionnaires will be returned to CTRC
alongside the relevant CRF treatment pages where
possible.
Data electronically stored at CTRC will be checked for
missing or unusual values (range checks) and checked
for consistency within participants. The trial monitoring
plan will detail methods in place to ensure reliability and
validity of the trial data. Any data that breaches these
checks will be returned to the site in the form of data
queries. Data query forms will be produced at the CTRC
from the trial database and sent either electronically or
through the post to a named individual (as listed on the
site delegation log). Sites will respond to the queries pro-
viding an explanation/resolution to the discrepancies
and return the data query forms to CTRC. The forms will
then be ﬁled along with the appropriate CRFs and the
appropriate corrections made on the database.
In order to perform their role effectively, the trial
coordinator (or monitor) and persons involved in
quality assurance and audit/inspection may need direct
access to primary data, for example, patient records,
laboratory reports, appointment books, etc. Since this
affects the patient’s conﬁdentiality, this fact is included
on the Patient Information Sheet and Informed
Consent Form.
A Trial Management Group (TMG) will be formed
comprising the Chief Investigator, other lead investiga-
tors (statistical, clinical and non-clinical) and members
of the CTRC. The TMG will be responsible for the
day-to-day running and management of the trial and will
meet approximately three times a year. A quorum of
three group members will be required to conduct a
TMG meeting.
The independent Data and Safety Monitoring
Committee (IDSMC) will consist of an independent
chairperson plus two independent members including a
statistician and clinician. The IDSMC will be responsible
for reviewing and assessing recruitment, interim moni-
toring of safety and effectiveness, trial conduct and
external data. The IDSMC will ﬁrst convene prior to the
start of recruitment and will then deﬁne frequency of
subsequent meetings (at least annually). The IDSMC
will provide a recommendation to the Trial Steering
Committee concerning the continuation of the study.
The Trial Steering Committee will oversee the trial.
Independent members will consist of an independent
chairperson, independent experts in the ﬁeld of visual
impairment following stroke and a biostatistician.
Non-independent members will consist of the local
Investigators. The role of the TSC is to provide overall
supervision for the trial and provide advice through its
independent Chairman. The ultimate decision for the
continuation of the trial lies with the TSC.
Patient and public involvement
This trial has involved a stroke survivor directly in the
development of this protocol ( JR) and will liaise closely
with her for advice and direction throughout the
conduct of the trial and in the dissemination process.
Involvement of stroke survivors in oversight committees
is also planned for this trial.
DISCUSSION
A recent Cochrane systematic review reported three
main approaches to visual rehabilitation: substitution,
adaptation or restitution.29 Following a comparison of
published data, the authors stated that generalisable
conclusions could not be reached regarding the use of
any approach to visual rehabilitation for homonymous
hemianopia because there was insufﬁcient high-quality
evidence. Based on limited evidence, it was indicated
that the greatest improvement in function, but not visual
ﬁeld defects, followed visual search training. It was
recommended that future RCTs should determine the
effect of compensatory scanning training OR restitutive
interventions OR substitutive interventions compared to
no treatment, control or placebo.29
There are no large scale RCTs to establish the effect-
iveness of prisms versus visual scanning training versus
no intervention. This trial will explore the effectiveness
of prism therapy (using base-out Fresnel prisms)and
visual search therapy (using paper-based visual scanning
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training) versus standard care (advice only with no inter-
vention). Outcome measures will include objective meas-
urement of visual ﬁelds and reading plus functional
measures by health-related and vision-related question-
naires of daily living.
This trial is designed as a pilot randomised controlled
trial to consider issues of recruitment and consent,
retention rates during the trial, compliance and adher-
ence with the interventions, appropriateness of blinding
procedures and randomisation, acceptability of the inter-
ventions and trial procedures to the participants and
investigators, appropriateness of outcome measurements
and logistics of multicentre procedures. The results of
the trial will provide information that could help to
improve allocation of treatment and resources in visual
rehabilitation post-stroke. This trial is funded by the UK
Stroke Association, is sponsored by the University of
Liverpool, has received multicentre ethical approval
through the North West 6 Research Ethics Committee
(Reference 10/H1003/119) and trial registration for
current controlled trials (ISRCTN05956042).
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